Q32 Bio named José Trevejo as chief medical officer.
Trevejo was chief medical officer and head of clinical pipeline strategy at Enveda Therapeutics.
Earlier roles include chief medical officer at Tarsus Pharmaceuticals, chief development officer at Rocket Pharmaceuticals, chief executive officer at SmartPharm Therapeutics.
Ellie Hershberger appointed chief development officer.
Hershberger previously served as chief development officer at Adagio Therapeutics, now Invivyd, leading its lead monoclonal antibody into Phase 3.
QTTB•
